Biogen Inc. (BIIB) Corporate Update
Trading Summary (Wednesday, 21 Oct 2026)
- Closing price: USD 243.10 (up 4.12 % from the previous close).
- Volume: USD 362.8 million worth of shares traded.
- Shares outstanding: 147.8 million.
- Market capitalization: USD 34.5 billion.
- Simple moving average (200 days): USD 198.44.
- 52‑week high: USD 244.65 (20 Oct 2026).
- 52‑week low: USD 138.00 (30 Oct 2025).
Recent Performance
- Since the end of the previous month, Biogen shares have risen 10.97 %.
- The stock contributed to the overall rise of the S&P 500, positioning the healthcare sector as one of the strongest performers in the market update.
Sector Context
- Biogen was highlighted as a leading performer among healthcare stocks.
- The healthcare sector’s gains were supported by positive momentum in other pharmaceutical names, including Moderna and Bristol‑Myers Squibb.
- No earnings or valuation metrics were disclosed; the emphasis remained on relative strength within the sector.
Peer Performance (Last 24 Hours)
| Symbol | Price (USD) | % Change | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|
| Sysco (SYY) | 82.89 | +1.59 % | 40.1 | 22.27 |
| Netapp (NTAP) | 209.97 | +1.25 % | 40.7 | 29.09 |
| Edison (ED) | 111.98 | +2.09 % | 40.6 | 17.98 |
| Live Nation (LYV) | 174.79 | +2.34 % | 39.8 | – |
| Illumina (ILMN) | 267.93 | +2.01 % | 39.7 | – |
Additional Corporate Highlights
- Netapp: CEO George Kurian received the 2026 Distinguished Leadership Award; the company was named North America Flash Partner of the Year for fiscal 2026.
- Edison: Shares experienced a modest decline in recent sessions, reflecting sector-wide pullbacks linked to rising bond yields and regulatory conditions.
- Live Nation & Illumina: Both maintained positive gains without notable corporate announcements.
Company Overview Biogen Inc. is headquartered in Cambridge, United States, and specializes in the development, manufacturing, and commercialization of therapies for neurological, oncological, and immunological diseases. Its product portfolio targets conditions such as multiple sclerosis, non‑Hodgkin lymphoma, rheumatoid arthritis, Crohn’s disease, and psoriasis. Biogen is listed on the Nasdaq stock exchange and conducted its initial public offering on September 16, 1991. For further information, visit the company’s website at www.biogen.com .
